Masahiko Hayakawa’s Post

Targeted Protein Degradation (TPD) has the potential to reshape the expectations of what is possible for many types of diseases by unlocking therapeutic targets previously deemed undruggable.     I believe it critical that we come together as an industry to share ideas and best practices to help accelerate the delivery of safe and effective protein degraders. That is why I was delighted to attend the 6th Annual TPD Summit in Boston, MA, to connect with other industry leaders and share invaluable insights. The conference reaffirmed how rapidly this field is advancing as a promising new modality, with an increasing number of clinical trials and developers focused on TPD. It was a privilege to share the progress @AstellasPharma is making in advancing a novel KRAS degrader with exciting first-in-class potential and discussing the speed with which we are advancing this program.     TPD is a promising technology that may bring a new era to the field of synthetic drug development. I am committed to leveraging our collective knowledge and collaborating with expert partners as we work to advance this exciting technology and create VALUE for patients around the globe.    #ScienceFirstForPatients #ChangingTomorrow #TargetedProteinDegradation